PledPharma AB announced that a number of internationally leading experts will join in a newly established Scientific Advisory Board to support the company during the continued clinical development of PledOx®. The aim of the Scientific Advisory Board is to give PledPharma valuable advice on the design of the remaining clinical trial program and the regulatory strategy for PledOx®, with the goal of maximizing the likelihood for regulatory approval and optimizing the drug candidate's commercial potential. The SAB will consist of internationally leading experts in oncology, neurology, chronic pain management and methods for measuring patients' reported outcome. The SAB will consist of Professor Guido Cavaletti, Professor David Cella, Professor emeritus Bengt Glimelius and Associate professor Rolf Karlsten. Guido Cavaletti was the Head of the Neuroimmunology Center at S. Gerardo Hospital and the Experimental Neurology Unit at the School of Medicine, University of Milan-Biocca in Monza, Italy and international expert in chemotherapy induced peripheral neuropathy. David Cella was the Chair of the Department of Medical Social Sciences at Northwestern University Feinberg School of Medicine in Chicago, USA. Glimelius was the Professor emeritus in oncology at the University of Uppsala and Consultant at the University hospital. Coordinating principal investigator in the PLIANT trial - PledPharma's Phase IIb Study with PledOx®. Rolf Karlsten was the Specialist in anesthesiology, intensive care and neuropathic pain management and Head of Rehabilitation Medicine and Pain Center at Uppsala Academic Hospital.